Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease DOI Creative Commons

Yu‐Ming Cheng,

Shaowen Wang,

C. H. Wang

et al.

Tzu Chi Medical Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

A BSTRACT Nonalcoholic fatty liver disease (NAFLD), first named in 1980, is currently the most common chronic disease, imposing significant health, social, and economic burdens. However, it defined as a diagnosis of exclusion, lacking clear underlying cause its diagnostic criteria. In 2020, metabolic dysfunction-associated (MAFLD) was proposed replacement for NAFLD, introducing additional criteria related to dysfunction. 2023, steatotic (MASLD) suggested replace aiming avoid stigmatizing term “fatty” incorporating cardiometabolic This divergence nomenclature between MAFLD MASLD presents challenges medical communication progress. review outlines pros cons both terminologies, based on current research evidence, hope fostering global consensus future.

Language: Английский

Steatotic liver disease DOI
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 404(10464), P. 1761 - 1778

Published: Nov. 1, 2024

Language: Английский

Citations

28
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis DOI Creative Commons
Michael H. Le, David Le,

Thomas C. Baez

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: 30(2), P. 235 - 246

Published: Jan. 29, 2024

Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence NAFLD-related events.

Language: Английский

Citations

24
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement DOI Creative Commons
Brian P. Lee, Katie Witkiewitz, Jessica L. Mellinger

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 21(9), P. 626 - 645

Published: June 7, 2024

Most patients with alcohol-associated liver disease (ALD) engage in heavy drinking defined as 4 or more drinks per day (56 g) 8 (112 week for women and 5 (70 15 (210 men. Although abstinence from alcohol after diagnosis of ALD improves life expectancy reduces the risk decompensation disease, few studies have evaluated whether treatment use disorders will reduce progression improve liver-related outcomes. In November 2021, National Institute Alcohol Abuse Alcoholism commissioned a task force that included hepatologists, addiction medicine specialists, statisticians, clinical trialists members regulatory agencies to develop recommendations design conduct trials evaluate effect use, particularly eliminate ALD. The conducted extensive reviews relevant literature on Findings were presented at one in-person meeting discussed over next 16 months final recommendations. As directly address this topic, 28 approved by all represent consensus expert opinions. Alcohol-associated is main cause morbidity mortality globally. This Consensus Statement makes design, best practice effects disorder.

Language: Английский

Citations

20
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States DOI
Donghee Kim, Karn Wijarnpreecha, George Cholankeril

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 33 - 42

Published: April 22, 2024

Recently, a panel of multi-society experts proposed steatotic liver disease (SLD) as an alternative terminology for metabolic dysfunction-associated fatty (MAFLD) or nonalcoholic (NAFLD).

Language: Английский

Citations

17
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050 DOI Creative Commons
Phuc Le, Moosa Tatar, Srinivasan Dasarathy

et al.

JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(1), P. e2454707 - e2454707

Published: Jan. 17, 2025

Importance Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common cause of chronic and projected to become leading indication for transplant (LT) in US. Understanding its clinical burden can help identify opportunities prevention treatment. Objective To project MASLD US adults from 2020 2050. Design, Setting, Participants This decision analytical modeling study used an agent-based state transition model that simulates natural history progression among 18 years age or older. Primary data sources inputs were published literature. Exposure Natural MASLD. Main Outcomes Measures Cases MASLD, metabolic steatohepatitis (MASH), fibrosis, hepatocellular carcinoma (HCC), LT, liver-related death. Results The simulated 2 821 624 individuals (mean age. 35.8 years; 50.9% female). predicted a steady increase prevalence 33.7% (86.3 million people) 41.4% (121.9 by MASH would 14.9 (5.8% adults) 23.2 (7.9% number cases clinically significant fibrosis (ie, F≥F2, centrilobular periportal more severe disease) estimated 6.7 11.7 million. By 2046 2050, 22 440 new HCC 6720 LT per year compared with 11 483 1717 2025. Liver-related mortality was 30 500 deaths (1.0% all-cause 95 300 (2.4%) Conclusions Relevance In this study, forecast substantial over next 3 decades absence effective treatments. These results suggest health systems should plan large increases need LT.

Language: Английский

Citations

8
Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality DOI
Nobuharu Tamaki, Takefumi Kimura,

Shun‐ichi Wakabayashi

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 61 - 69

Published: April 25, 2024

Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated (MASLD), MASLD and increased alcohol intake (MetALD) alcohol‐associated (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) all‐cause mortality among various sub‐groups is unknown. Aims To evaluate MACE death patients with SLD. Methods We conducted nationwide, population‐based study enrolled 761,400 diagnosed MASLD, MetALD or ALD. The primary endpoint was occurrence in Results cumulative incidence were highest ALD, followed by ( p < 0.001 both death), while ALD 0.001). Using as reference adjusting age, sex, smoking, diabetes mellitus, dyslipidaemia hypertension, adjusted hazard ratios (95% confidence intervals) 1.42 (1.1–1.8), 0.68 (0.63–0.73) 1.13 (0.98–1.3), respectively. In they 3.42 (2.6–4.6), 0.58 (0.49–0.67) 1.60 (1.3–2.0), respectively, death. Conclusions can be used to stratify complications prognosis. beneficial stratification identifying mechanisms disease‐specific therapeutic implications.

Language: Английский

Citations

14
Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA DOI Creative Commons
Alexander H. Yang, Monica A. Tincopa, Federica Tavaglione

et al.

Gut, Journal Year: 2024, Volume and Issue: 73(12), P. 2045 - 2053

Published: Aug. 7, 2024

There are limited prospective data among overweight and obese individuals on the prevalence of advanced fibrosis, cirrhosis using MRI-based methods in USA. The aim this study was to fill that gap knowledge by prospectively determining steatotic liver disease (SLD) its subcategories, fibrosis residing

Language: Английский

Citations

14
Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study DOI Open Access
Takao Miwa, Satoko Tajirika, Nanako Imamura

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(4), P. 1158 - 1158

Published: Feb. 19, 2024

This cross-sectional study examined the prevalence and characteristics of steatotic liver disease (SLD) based on a recently introduced nomenclature in Japanese health checkup population. SLD was evaluated using ultrasonography, participants were categorized into metabolic dysfunction-associated (MASLD), dysfunction alcohol associated (MetALD), alcohol-associated/related (ALD), cryptogenic groups. The subclasses assessed, subgroup analyses conducted for non-obese (body mass index [BMI] ≤ 25 kg/m2) lean (BMI 23 populations. Among 694 participants, with median age 47 years comprising 54% males, MASLD, MetALD, ALD, 26%, 2%, 1%, respectively. A remarkable difference observed according to age, sex, BMI. Subgroup revealed heterogeneous demographic, clinical, biochemical parameters between categories. Individuals MetALD had higher gamma-glutamyl transferase levels, lower platelet counts, fibrosis-4 than did those MASLD. Furthermore, MASLD 13% 6%, provides preliminary information new

Language: Английский

Citations

13
Metabolic characteristics of patients with MetALD: Caveats of a new definition DOI

Erin Petrie,

Meagan Gray, Fernando Bril

et al.

Liver International, Journal Year: 2024, Volume and Issue: 44(11), P. 2929 - 2938

Published: Aug. 17, 2024

Abstract Background and Aims Recently, a new entity was introduced, MetALD, which includes patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), who consume moderate amounts of alcohol. However, little is known regarding the clinical characteristics these patients. Methods Data from National Health Nutrition Examination Surveys 2017–2020 used. Participants without valid transient elastography (TE) measurements, incomplete alcohol consumption report, or alternative etiologies steatosis were excluded. Results A total 6901 included in study, 106 (1.5%) had MetALD. Overall, MetALD showed profile that more similar to related (ALD) than MASLD. Specifically, while values in‐between MASLD ALD for body mass index (BMI), aspartate transaminase (AST), alanine (ALT), gamma glutamyltransferase (GGT) haemoglobin A1c, they high‐density lipoprotein cholesterol (HDL‐C), blood pressure, prevalence diabetes insulin resistance Increasing associated lower A1c higher triglycerides, HDL‐C pressure. Moreover, AST, ALT GGT increased consumption, this did not translate into worse hepatic fibrosis by TE. Conclusions share some MASLD, but resemble more, especially after adjusting BMI. Alcohol produces dissociation between cardiometabolic risk factors (blood pressure HDL‐C), may make current classification challenging.

Language: Английский

Citations

12
Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population DOI Creative Commons
Haoxuan Zou, Xiaopu Ma, Wen Pan

et al.

Frontiers in Nutrition, Journal Year: 2024, Volume and Issue: 11

Published: July 8, 2024

Background Recently, the multisociety Delphi consensus renamed non-alcoholic fatty liver disease (NAFLD) terminology [previously metabolic-associated (MAFLD)] as metabolic dysfunction-associated steatotic (MASLD). The aim of this study was to compare similarities and differences between NAFLD, MAFLD, MASLD clarify impact new name change. Methods A cross-sectional 3,035 general subjects with valid vibration-controlled transient elastography data conducted based on from National Health Nutrition Examination Survey (NHANES) 2017–2020. were defined according corresponding criteria. Results Using controlled attenuation parameter (CAP) ≥274 dB/m stiffness measurements (LSM) ≥9.7 kPa cutoff values for presence hepatic steatosis advanced fibrosis (ALF), prevalence 38.01% (95% CI 35.78–40.29%), 41.09% (39.09–43.12%), 37.9% (35.70–40.14%), respectively, ALF 10.21% (7.09–14.48%), 10.13% (7.06-14.35%), 10.24% (7.11–14.53%), respectively. kappa three definitions above 0.9. severity remained similar when sensitivity analyses performed using different CAP thresholds. MASLD, increased number cardiometabolic risk factors (CMRF) increased. Conclusions Our findings highlight consistency among definitions, especially NAFLD so that will not disturb original NAFLD-related findings. Additionally, more attention should be paid patients a high CMRFs.

Language: Английский

Citations

10